Barut, ZerrinAkdeniz, Fatma TubaIsbir, TurgayGenetik ve Biyomühendislik / Genetic and Bio-Engineering2024-05-252024-05-25202400250-70051791-753010.21873/anticanres.168472-s2.0-85183795013https://doi.org/10.21873/anticanres.16847https://hdl.handle.net/20.500.14517/1130Background/ Aim: Lung cancer remains a principal cause of cancer-related mortality worldwide. Non-small cell lung cancer (NSCLC), representing a significant 80-85% of lung cancer diagnoses, often presents at an advanced stage, with many patients demonstrating local growth or metastasis at the time of detection. Consequently, there exists a pressing need for augmented research into the molecular and genetic underpinnings of this malignancy to facilitate the development of innovative therapeutic and preventative strategies. MicroRNA's (miRNAs) are non-coding RNA molecules, consisting of 20-25 nucleotides. Their involvement in epigenetic processes holds a pivotal role in the elucidation of molecular mechanisms. This study examined the potential of miRNA-223-3p as a biomarker in the diagnosis of patients with NSCLC. Materials and Methods: The expression analysis of miRNA-223-3p was performed in serum samples obtained from 18 patients diagnosed with NSCLC and a control group comprising 15 healthy volunteers. Results: The miRNA-223-3p Delta CT values in the serum samples taken from the patient group exhibited statistically significant elevation compared to those of the control group (p=0.043). Conclusion: The present study corroborates previous literature indicating elevated levels of miRNA-223-3p in NSCLC cases and thereby suggesting its potential role as a biomarker in NSCLC cases.eninfo:eu-repo/semantics/closedAccessNSCLCmiRNA-223-3pPCRbiomarkerArticleQ4Q3442585591WOS:00116063720000438307576